BCRX BioCryst Pharmaceuticals, Inc.

-0.96  -14%
Previous Close 6.73
Open 6.65
Price To book 14.05
Market Cap 464.02M
Shares 80,420,000
Volume 7,305,452
Short Ratio 3.60
Av. Daily Volume 2,306,230

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Phase 2 interim data released February 27, 2017. Top-line data released May 25, 2017.
BCX7353 - APeX-1
Reduce or eliminate attacks in HAE patients
Approved Dec 22 2014
Peramivir - Study 303

Latest News

  1. Why Zoe's Kitchen, Beazer Homes, and BioCryst Pharmaceuticals Slumped Today
  2. BioCryst and Aerie Pharmaceuticals' Shares Swell on Positive Study Results
  3. Why BioCryst Pharmaceuticals Stock Caught Fire Today
  4. Stocks rise for Aerie, BioCryst following positive trial results
  5. Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring
  6. BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial
  7. Shire's swelling disorder drug moves closer to U.S. approval
  8. Implied Volatility Surging for BioCryst (BCRX) Stock Options
  9. Edited Transcript of BCRX earnings conference call or presentation 4-May-17 3:00pm GMT
  10. BioCryst to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
  11. Today's Research Reports on Biotech Stocks to Watch: BioCryst Pharmaceuticals and Keryx Biopharmaceuticals
  12. Investor Network: BioCryst Pharmaceuticals, Inc. to Host Earnings Call
  13. BioCryst reports 1Q loss
  14. BioCryst Reports First Quarter 2017 Financial Results
  15. BioCryst to Announce First Quarter 2017 Financial Results May 4
  16. After announcing a $45M public offering, BioCryst to launch new trial
  17. BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
  18. BioCryst to receive royalties from cancer treatment approved in Japan
  19. Stocks of companies with Raleigh-Durham area HQ make a comeback in March
  20. BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan